Research Projects

Osteosarcoma (OS) and Ewing Sarcoma (EW) are the most frequent malignant primary bone tumors in children and adolescents, with a mean incidence during the second decade of life. The first line of therapy consists in neoadjuvant poly-chemotherapy, surgical resection followed by adjuvant chemotherapy. Despite improvements in surgical techniques and poly-chemotherapy development, survival rates are still around 70% at 5 years for localized tumors and only 25% for patients with resistance to conventional treatment or metastasis. So far, no clear oncogenic drivers have been identified for OS. Regarding the therapeutic resistance mechanisms, except classical processes like the multidrug resistance phenotype (MDR), no specific mechanisms have been identified as drivers. Therefore, it becomes necessary to explore other possible origins to OS therapeutic resistance and metastatic dissemination studying combinations of unknown transcriptional regulatory circuitries and signaling pathways at the origin of OS development in order to validate innovative therapeutic approaches to improve the medical response of OS. In this context, we decided to study the implication of chromatin and transcriptional deregulation in metastatic dissemination and resistance development. We use an association of various in vitro models, in vivo models, PDX, patient samples, single cells and bioinformatics tools.



Benjamin Ory, MCU
François Lamoureux, CR Inserm

Franck Verrecchia, DR Inserm
Françoise Redini, DR Inserm
Bénédicte Brounais-Le-Royer, MCU
Steven Georges, MCU
Marc Baud’huin, MCU-PH
Vincent Crenn, PU-PH
Helios Bertin, MCU-PH
Morgane Cleirec, PH

Régis Brion, IE
Rose-Anne Thepault, TR
Céline Charrier, TR
Séverine Battaglia, IE
Jérôme Amiaud, TR
Frédéric Jacquot IE
Anaïs Postec, AI
Laura Regnier, TN
Mathilde Mullard, IE

Morgane Lallier, PhD Student
Maryne Dupuy, PhD Student
Louise Marchandet, PhD Student
Mélanie Lavaud, PhD Student
Emilien Orgebin, PhD Student
Robel Tesfaye, PhD Student

Main Publications